Dare Bioscience GAAP EPS of -$0.18 misses by $0.02
Dare Bioscience reported Q3 GAAP EPS of -$0.18, missing estimates by $0.02. Revenue rose to $48,000 from $2,300 year-over-year, according to the company.
Dare Bioscience, Inc.
Daré Bioscience is a health biotechnology company focused on developing and commercializing products for women’s health. Its portfolio spans contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Daré pursues FDA approval, Section 503B compounding and non-prescription consumer products as pathways to market, and earns money through commercial product sales and licensing arrangements. Its products include DARE to PLAY, a compounded sildenafil cream; the planned DARE to RESTORE line of vaginal probiotic suppositories, beginning with Flora Sync LF5; and investigational candidates including Ovaprene, a hormone-free monthly contraceptive. XACIATO, an FDA-approved vaginal gel for bacterial vaginosis, is licensed to Organon for commercialization. Daré also has DARE-HRT1, an intravaginal hormone therapy candidate. The company is headquartered in San Diego, California.
No SEC Form 4 filings for $DARE in the last 30 days.
See all $DARE insider activity →Dare Bioscience reported Q3 GAAP EPS of -$0.18, missing estimates by $0.02. Revenue rose to $48,000 from $2,300 year-over-year, according to the company.
Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement DARE to PLAY™ Sildenafil Cream prescription dispensing activities underway this month, with prescriptions written across 48 states and Washington
Dare Bioscience (DARE) will report Q3'26 earnings on November 16. Analysts expect $2.04M revenue and a loss of $0.13 per share. Results will be released after market close.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning DARE (Dare Bioscience, Inc.). Coverage has skewed bearish: 1 bullish, 1 neutral, and 2 bearish.
Recent DARE coverage spans earnings, corporate actions and technology.
Earnings miss plus extreme year-over-year revenue swing likely drives near-term downside risk and raises questions about underlying operating trajectory.
Near-term catalyst is operational readiness for prescription dispensing, which could improve near-term demand visibility and revenue ramp expectations.
Negative earnings estimate may pressure the stock ahead of the actual release.
The vote results are routine corporate governance information with no material change to capital structure or operations.
The new grant funding supports continued preclinical work and may reduce dilution concerns, modestly improving sentiment.
AlphAI scores every news story that mentions DARE with an AI model for sentiment and relevance, and aggregates insider trades from Dare Bioscience, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Dare Bioscience reported Q3 GAAP EPS of -$0.18, missing estimates by $0.02. Revenue rose to $48,000 from $2,300 year-over-year, according to the company.
Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement DARE to PLAY™ Sildenafil Cream prescription dispensing activities underway this month, with prescriptions written across 48 states and Washington
Dare Bioscience (DARE) will report Q3'26 earnings on November 16. Analysts expect $2.04M revenue and a loss of $0.13 per share. Results will be released after market close.
Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. A special meeting of stockholders (the “Meeting”) of Daré Bioscience, Inc. (“Daré,” “we,” “us,” or “our”) was held on November 10, 2026 and the following proposals were voted upon by our stockholders. The proposals ar
Daré Bioscience (NASDAQ: DARE) received $1.5 million in additional funding for its DARE-LARC1 contraceptive implant. The company believes its DARE-IDDS platform could extend to other chronic diseases, like obesity and diabetes. Daré is exploring strategic collaborations and expects to advance DARE-LARC1 toward an IND submission.
Dare Bioscience (DARE) is scheduled to release Q3'26 earnings on November 05. Analysts expect revenue of 1.57M USD and EPS of (0.16) USD. The announcement is expected at 7:00 AM ET (12:00 PM UTC).
Daré Bioscience (NASDAQ: DARE) will present Phase 1 data on its Sildenafil Cream at the SMSNA Annual Fall Scientific Meeting. The study showed lower systemic exposure compared to oral sildenafil, with no serious adverse events. The company is developing the cream as a potential treatment for female sexual arousal disorder (FSAD), for which there are currently no FDA-approved treatments.
Daré Bioscience (DARE) received a notice from Nasdaq on September 28, 2026, for failing to maintain a $1.00 minimum bid price for 30 consecutive days. The company has until March 29, 2027, to comply, with a possible 180-day extension if criteria are met.
Dare Bioscience (DARE) released a corporate presentation on October 1, 2026, for use in investor meetings. The presentation will be posted on the company's website under the Investors section. The information is furnished under Regulation FD Disclosure and is not incorporated into other SEC filings unless stated.
Daré Bioscience (DARE) reported Phase 1 data for its Sildenafil Cream, showing lower systemic exposure than oral sildenafil. The study, published in Sexual Medicine, involved 62 healthy men and found significantly lower plasma concentrations for topical administration. The cream is being developed for women's sexual health. DARE stock is currently trading at $0.71, up 0.69%.